NCT06034002
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06034002
Title A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications
essential thrombocythemia
myelofibrosis
Therapies
INCA033989 + Ruxolitinib
INCA033989
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Medical Center RECRUITING Duarte California 91010 United States Details
Stanford Cancer Institute RECRUITING Palo Alto California 94304 United States Details
University of Miami Health System RECRUITING Miami Florida 33136 United States Details
The University of Kansas Cancer Center RECRUITING Westwood Kansas 66205 United States Details
Johns Hopkins Hospital RECRUITING Baltimore Maryland 21287 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Washington University School of Medicine RECRUITING St Louis Missouri 63108 United States Details
Icahn School of Medicine At Mount Sinai RECRUITING New York New York 10029 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
Wake Forest Baptist Medical Center RECRUITING Winston-Salem North Carolina 27157 United States Details
Cleveland Clinic RECRUITING Cleveland Ohio 44195 United States Details
Vanderbilt University Medical Center RECRUITING Nashville Tennessee 37232 United States Details
Md Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field